THE HEMATOLOGIC TROJAN HORSE: CLONAL HEMATOPOIESIS AND THE NEXT  FRONTIER OF CARDIOVASCULAR MEDICINE                                   

Abstract

For decades, cardiovascular risk reduction has centered on lipids, blood pressure, glycemic control, and smoking yet a substantial burden of residual risk remains unexplained. One previously unknown cause of this residual risk is Clonal Hematopoiesis of Indeterminate Potential (CHIP), which is the age-related growth of hematopoietic stem cell clones with somatic mutations in genes like TET2, DNMT3A, and ASXL1. Atherosclerotic plaque instability, adverse ventricular remodeling, heart failure progression, and valvular calcification are all accelerated by hyperactivation of the NLRP3 inflammasome and excess IL-1β/IL-6 secretion caused by mutant monocyte-derived macrophages infiltrating the vasculature, myocardium, and cardiac valves. Exploratory analyses of the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) trial also indicate that CHIP carriers, especially those with TET2 mutations, benefit more from IL-1β-targeted anti-inflammatory therapy. These findings support a paradigm shift toward genotype-directed precision cardiology and argue for dedicated Cardio-Hematology clinical frameworks to identify, monitor, and treat this newly defined at-risk population. Clinical cohort data link CHIP to increased risk of coronary heart disease, early-onset myocardial infarction, and mortality following transcatheter aortic valve implantation.